Bibliographic Info
GuidelineGuidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection.
Year of Publication2024
Issuing InstitutionWHO
Recommendation
Status
Maintained
Recommended against
Strong
Certainty of evidence
Moderate
First-line antiviral therapies for chronic hepatitis B. Nucleoside analogues with a low genetic barrier to resistance (lamivudine, adefovir or telbivudine) can lead to drug resistance and are not recommended
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
Year2015
InstitutionWorld Health Organization